| Ilan Danieli |
Ilan Danieli is the founder of Precipio Diagnostics LLC, which was founded in 2011. He is currently the Chief Executive Officer & Director at Precipio, Inc. since 2017. He is also a Manager at IDP Holdings LLC. Previously, he held the position of President, Chief Executive Officer & Director at Transgenomic, Inc. He was the Marketing Director at Magnolia Broadband, Inc. from 2000 to 2002. From 2005 to 2007, he served as the Vice President-Operations at Laurus Capital Management LLC. He was also the Chief Operating Officer at Osiris Corp. Mr. Danieli received his undergraduate degree from Bar-Ilan University in 1996 and his MBA from the University of Virginia Darden School of Business in 2000. |
| Miri Chiko-Radomski |
Miri Chiko-Radomski is currently the Chief Legal Counsel & People Officer at Precipio, Inc. She has a graduate degree from the University of East Anglia and another graduate degree from King's College London. |
| Ayman A. Mohamed |
Ayman A. Mohamed is the founder of Precipio Diagnostics LLC. He is currently working as the Chief Technology Officer at Precipio, Inc. Previously, he worked as the Vice President-Research & Development at Transgenomic, Inc. Dr. Mohamed completed his graduate and doctorate degrees at Alexandria University. |
| Ahmed Zaki Sabet |
Ahmed Zaki Sabet is the founder of Precipio Diagnostics LLC, which was founded in 2017. He holds the title of Chief Operating Officer at Precipio Diagnostics LLC. Mr. Sabet's current job is Chief Operating Officer at Precipio, Inc., starting in 2018. Mr. Sabet's former job was Vice President-Operations at Transgenomic, Inc. Mr. Sabet's education history includes an undergraduate degree from New Jersey Institute of Technology. |
| Richard Alvin Sandberg |
Richard Alvin Sandberg founded DIANON Systems, Inc. in 1983, where he worked as Chairman, Chief Executive & Financial Officer from 1983 to 1997. Mr. Sandberg also currently works at Resolys Bio, Inc., as Co-Chairman & Chief Executive Officer from 2017, Precipio Diagnostics LLC, as Chairman, Oxford Immunotec Ltd., as Chairman from 2008, Precipio, Inc., as Independent Chairman from 2021, Quest Diagnostics TB LLC, as Independent Director from 2019, and Abcodia Ltd., as Non-Executive Director. Mr. Sandberg also formerly worked at Lifecodes Corp., as Chairman & Chief Financial Officer from 1997 to 2001, OBS Medical Ltd., as Non-Executive Chairman from 2015 to 2017, Concile GmbH, as Chairman, SuperNova Diagnostics, Inc., as Chairman, Jupiter Diagnostics Ltd., as Chairman-Elect, Matritech, Inc., as Chief Financial Officer & Director, Ethan Allen Interiors, Inc., as Director from 2003 to 2009, North American Scientific, Inc., as Director from 2005 to 2009, Cylex, Inc., as Director in 2010, Precipio Diagnostics LLC, as Director, Oxford Immunotec Global Ltd., as Independent Director from 2019 to 2021, MZT Holdings, Inc., as Director from 1999 to 2008, Jupiter Diagnostics Holding Co. Ltd., as Director, Critical Care Diagnostics, Inc., as Chief Financial Officer, and Battery Asset Management LLC, as Chief Financial Officer from 2004 to 2007. Mr. Sandberg received his undergraduate degree from Northwestern University. |
| Kathy D. LaPorte |
Kathy D. LaPorte is the founder. She founded New Leaf Venture Partners LLC in 2005, where she held the title of Partner. Ms. LaPorte is also the founder of HealthTech Capital Co...Ms. LaPorte's current job(s) include being a Director at Aesthetic Sciences Corp., Precipio Diagnostics LLC, Bolt Biotherapeutics, Inc., Precipio, Inc., Elysium Therapeutics, Inc., 89bio, Inc., Q32 Bio Operations, Inc., D2G Oncology, Inc., CERo Therapeutics Holdings, Inc., and Q32 Bio, Inc.Ms. LaPorte's former job(s) include being the Chief Executive Officer at Nodality, Inc., a Director at Cytyc Prenatal Products Corp., Onyx Pharmaceuticals, Inc., ISTA Pharmaceuticals, Inc., VNUS Medical Technologies, Inc., Transcept Pharmaceuticals, Inc. (Old), eHealth, Inc., Affymax, Inc., Cellgate, Inc., Prometheus Laboratories, Inc., eHealthInsurance Services, Inc., the California Institute for Regenerative Medicine, Pearl Therapeutics, Inc., Transcept Pharma, Inc., Phoenix Biotech Acquisition Corp., and First Boston Corp. She was also a General Partner at Sprout Group and Credit Suisse Securities (USA) LLC, and the President of the Western Association of Venture Capitalists. Ms. LaPorte's education history includes an undergraduate degree from Yale University in 1983 and an MBA from Stanford Graduate School of Business in 1987. |
| David S. Cohen |
David S. Cohen is the founder of My Gene Counsel LLC (founded in 2014) and ResCom Energy LLC (founded in 2009), where he holds the title of President. Mr. Cohen is also the founder of Standard Security Systems, Moneo Technology Solutions LLC, Standard Oil Ventures LLC, and Foresite MSP, Inc. Mr. Cohen's current job(s) include being a Director at EpiEP, Inc., Phoenix Vintners LLC, Precipio Diagnostics LLC, eBrevia, Inc., iMedX, Inc., Betatronix LLC, The Platt & LaBonia Co LLC, InCytu, Inc.,. Sirona Medical Technologies, Inc., Precipio, Inc. (since 2017), Emme Controls LLC, CPA Innovations LLC, BloomBoard, Inc., ZoneFlow Reactor Technologies LLC, Omnio Group Ltd., Genixo Construction LLC, and Standard Oil of Connecticut, Inc. (where he holds the title of Chief Operating Officer). Mr. Cohen's former job(s) include being a Director at SOMS Technologies LLC and gomembers, Inc.Mr. Cohen's education history includes attending Harvard College, where he received his undergraduate degree in 1980. |
| Christina Valauri |
Ms. Christina Valauri is Managing Director & Global Director of Research at Cantor Fitzgerald Securities and Global Director of Research at Cantor Fitzgerald & Co.
Prior to joining Cantor Fitzgerald, Ms. Valauri was previously employed by Natixis, where she served as Managing Director and Director of U.S. Equity Research, as well as Global Director of Equity Research product for Healthcare, Energy and Commodities, and served as a senior member of the broker dealer management team for Natixis Securities Americas, LLC. Prior to that, she was Director of Equity Research and a Founding Partner of Broadpoint Capital, formerly First Albany Capital. She is a member of the New York Society of Security Analysts, CFA Institute, Global Association of Risk Professionals, and International Corporate Governance Network. She also worked for ING Barings LLC, Credit Lyonnais and Gleacher & Co., Inc.
Ms. Valauri holds a B.A. in Biology from Reed College. |
| Jeffrey Cossman |
Jeffrey Cossman was the founder of USDS, Inc. (founded in 2009) where he held the title of Chairman & President from 2013 to 2014. Dr. Cossman is also the founder of Avalon Pharmaceuticals, Inc., Association for Molecular Pathology, Halcyon Diagnostics, Inc. Dr. Cossman's current job is as a Director at Precipio Diagnostics LLC. He is also an Independent Director at Precipio, Inc. since 2017. Dr. Cossman's former jobs include being the Chairman-Pathology Department & Professor at Georgetown University Medical Center, Medical Director & Vice President at Gene Logic, Inc., Secretary & Director at Personalized Medicine Coalition from 2008 to 2014, and Senior Investigator Hematopathology at National Cancer Institute. He also served as the Chief Science Officer at Critical Path Institute. Dr. Cossman obtained a doctorate degree from the University of Michigan and a graduate degree from the University of Michigan Medical School. |
| Ronald Asbury Andrews |
Ronald Asbury Andrews is the founder of Bethesda Group Fund, which was founded in 2015. He held the title of Principal at Bethesda Group Fund. Mr. Andrews's current job(s) include being the Chief Executive Officer & Director at Twinstrand Biosciences, Inc., the Non-Executive Chairman at Dxcover Ltd., the Executive Chairman at SimBioSys, Inc., a Director at Oxford Immunotec Ltd., a Director at Mission Hospital Foundation, an Independent Director at Orion Health Ltd., a Director at Quest Diagnostics TB LLC, a Director at Insight Genetics, Inc., an Independent Director at Cellmax, Inc., an Independent Director at Precipio, Inc., a Trustee at Wofford College, and a Member-Supervisory Board at Agendia, Inc.Mr. Andrews's former job(s) include being the Chief Executive Officer-GE Molecular Diagnostics at Clarient, Inc. from 2010 to 2012, the Chief Executive Officer-Clarient Business Unit at GE Healthcare, Inc. in 2012, the Chief Executive Officer & Director at OncoCyte Corp. from 2018 to 2022, an Independent Non-Executive Director at Oxford Immunotec Global Ltd. from 2015 to 2021, a Director at Cardiac Science Corp. from 2009 to 2010, an Independent Director at Orion Health Group Ltd. from 2016 to 2018, a Vice President at Immucor, Inc., a Vice President-Marketing at Roche Diagnostics Corp., the President-Genetic Sciences Division at Thermo Fisher Scientific, Inc. from 2013 to 2014, a Senior Vice President-Global Marketing at Roche Molecular Systems, Inc. from 2000 to 2004, a Senior Marketing Manager-Business Unit Operations at Abbott Diagnostics, Inc., the President-Medical Sciences at Life Technologies Corp. from 2012 to 2013, a Member-Governors Board at CancerLinQ LLC from 2016 to 2023, and a Managing Partner at Ph Blueprint. Mr. Andrews's education history includes obtaining an undergraduate degree from Wofford College in 1981. |
